Carmell Therapeutics Announces Appointment of Randy Hubbell to President and Chief Executive Officer

PITTSBURGH, Feb. 16, 2016 /PRNewswire/ -- Carmell Therapeutics announced today the appointment of Randy Hubbell to President and Chief Executive Officer. Former CEO, Alan West, has successfully positioned Carmell Therapeutics towards initiation of pivotal study for FDA BLA (Biologics License Application) approval and will stay on as a Chief Operating Officer.

Mr. Hubbell is a highly experienced business leader with significant experience in commercialization of transformational medical devices as well as drug device combination products.  Mr. Hubbell's most recent leadership role was as Chief Commercial Officer for Cardiva Medical, which received PMA (pre-market approval) for the next generation vascular closure device in 2013. At Cardiva, Mr. Hubbell designed, implemented and executed against a successful go-to-market strategy.  Prior to Cardiva, Mr. Hubbell spent 13 years as a member of various management boards at Johnson & Johnson (J&J); Ethicon Biosurgery, Pharmaceutical Group Strategic Marketing (PGSM) and Cordis. During those years, he was a key member of leadership teams that oversaw the development and commercialization of CYPHER^®, the first drug-eluting stent, IONSYS^®, a novel post-op pain drug (fentanyl) delivery device and EVARREST^®, a transformational biologic hemostat.   Before J&J, Mr. Hubbell worked at two start-ups (Enmed & VASCA/NxStage Medical), Boston Scientific and IBM. He holds a B.S. in Computer Science from Tulane University and an M.B.A. from Loyola University of the South.

"Carmell Therapeutics will benefit significantly from Mr. Hubbell's experience and knowledge related to bringing transformational drug device combination products to market. Mr. Hubbell's leadership experience at Ethicon Biosurgery, where he championed transformational projects through product development, FDA BLA regulatory approval and commercialization, will be especially relevant in driving the next phases of Carmell's success," said Bill Newlin, Carmell Board Chairman and General Partner, Newlin Investment Company.

Mr. Hubbell commented, "I believe Carmell has created a revolutionary technology that will enhance the healing process through the innovative delivery of naturally-derived active biologics. Carmell's patented technology is unique in its ability to be delivered in various forms with predetermined (days, weeks or months) and controlled release of active biologics. Carmell's technology is unlike anything on the market or in development today and I look forward to introducing this innovative and highly differentiated healing solution to physicians and patients."

About Carmell Therapeutics Corporation

Plasma-Based Materials – Using the Body to Heal Itself
Founded in 2007 as a spin out from Carnegie Mellon University in Pittsburgh, PA, Carmell Therapeutics has created a unique, highly innovative, patented technology based on biologically-active adaptive materials manufactured from human blood plasma. These plasma-based materials contain a concentration of natural regenerative factors that promote healing, reduce complications, and lead to healthcare savings. Unlike previous approaches to delivering growth factors to injuries/surgeries, Carmell's plasma-based devices can be designed to vary the release time of active biologics to accommodate the needs of the body. The company has successfully developed multiple forms, such as pastes, putties, scaffolds, plugs and screws, using pooled plasma from healthy donors with its proprietary cross-linking process. Carmell's first product, REPAIR™ putty, is designed to treat bone fractures through accelerated bone healing of the fracture and surrounding soft tissues while reducing complications, infections and duration of care. Early human clinical evidence suggests that REPAIR putty is efficacious, safe, consistent and affordable.

For more information on Carmell Therapeutics, please visit the Company's website at http://www.carmellrx.com/

CONTACT: Carmell: Randy Hubbell, +1-412-208-8033  

SOURCE Carmell Therapeutics Corporation

Related Links

http://www.carmellrx.com